Related Experiment Videos
Mitomycin therapy in gastric cancer
1Temple University Comprehensive Cancer Center, Philadelphia, PA 19140.
Abstract:
Adenocarcinoma of the stomach remains a significant cause of mortality worldwide. The majority of patients present with stage III or IV disease, negating surgery as a curative option. Numerous drugs have been tested over the past 2 decades in single-agent and combination chemotherapy trials. Given by intravenous bolus, mitomycin has induced responses as high as 63% and as low as 24% in patients with various gastrointestinal malignancies. Mitomycin has also demonstrated efficacy when given in combination with doxorubicin and in the three-drug regimen FAM (5-fluorouracil/doxorubicin/mitomycin). FAM has been explored in multiple phase II and III trials and has become the standard with which many new combinations are compared. Compared with other doxorubicin-containing regimens, it has demonstrated the longest median survival (29.5 weeks) and the lowest incidence of severe toxicity. The addition of semustine or leucovorin to FAM has yielded responses comparable with those attained by FAM alone. In Japan, where treatment of gastric cancer has been more successful, possibly due to earlier diagnosis and more aggressive surgical approaches, mitomycin has been given intraperitoneally during surgery and postoperatively in combination with fluorinated pyrimidines or other agents. Mitomycin will undoubtedly play a role in the development of new approaches to the treatment of gastric cancer.
Insights
Mitomycin, a chemotherapy drug, shows varied response rates in gastrointestinal cancers. It is effective in combination regimens like FAM (5-fluorouracil/doxorubicin/mitomycin), offering improved survival and reduced toxicity for stomach cancer patients.
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Medical Pharmacology
Background:
- Gastric adenocarcinoma is a leading cause of cancer mortality globally.
- Most patients are diagnosed with advanced-stage disease (III or IV), limiting surgical curability.
- Chemotherapy is a critical treatment modality for advanced gastric cancer.
Purpose of the Study:
- To review the efficacy and role of mitomycin in the treatment of gastric adenocarcinoma.
- To evaluate mitomycin's performance in various chemotherapy regimens, including single-agent and combination therapies.
- To discuss the potential of mitomycin in future gastric cancer treatment strategies.
Main Methods:
- Review of existing clinical trials and literature on mitomycin in gastrointestinal malignancies.
- Analysis of response rates, median survival, and toxicity profiles of mitomycin-based regimens.
- Comparison of mitomycin-containing regimens, such as FAM (5-fluorouracil/doxorubicin/mitomycin), with other treatment options.
Main Results:
- Intravenous mitomycin has shown response rates ranging from 24% to 63% in gastrointestinal malignancies.
- The FAM regimen (5-fluorouracil/doxorubicin/mitomycin) demonstrated a median survival of 29.5 weeks and lower toxicity compared to other doxorubicin regimens.
- Addition of semustine or leucovorin to FAM did not significantly improve response rates.
Conclusions:
- Mitomycin is an effective agent in treating gastric adenocarcinoma, particularly within combination chemotherapy regimens like FAM.
- The FAM regimen represents a standard treatment option, offering a balance of efficacy and safety.
- Intraperitoneal administration of mitomycin in Japan suggests potential for novel therapeutic approaches in gastric cancer treatment.